List of Varubi drug patents
Varubi is owned by Tersera.
Varubi contains Rolapitant Hydrochloride.
Varubi has a total of 9 drug patents out of which 1 drug patent has expired.
Expired drug patents of Varubi are:
- US8796299
Varubi was authorised for market use on 01 September, 2015.
Varubi is available in tablet;oral dosage forms.
Varubi can be used as prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy.
The generics of Varubi are possible to be released after 14 July, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8178550 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Apr, 2027
(4 years from now) | |
| US7049320 | TERSERA | NK1 antagonists |
Aug, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796299 | TERSERA | NK1 antagonists |
Dec, 2022
(3 months ago) | |
| US7981905 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(4 years from now) | |
| US8404702 | TERSERA | Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(4 years from now) | |
| US7563801 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(4 years from now) | |
| US8470842 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Jan, 2029
(5 years from now) | |
| US8361500 | TERSERA | Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom |
Oct, 2029
(6 years from now) | |
| US9101615 | TERSERA | Intravenous formulations of neurokinin-1 antagonists |
Jul, 2032
(9 years from now) | |
Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient
Market Authorisation Date: 01 September, 2015
Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy
Dosage: TABLET;ORAL
VARUBI family patents
31
United States
16
Japan
11
European Union
7
Peru
7
China
6
Singapore
6
Spain
6
Taiwan, Province of China
6
Canada
5
Mexico
5
Argentina
4
Brazil
4
Korea, Republic of
3
Australia
3
Hong Kong
3
Russia
3
Hungary
3
Norway
3
New Zealand
2
South Africa
2
Austria
2
Lithuania
2
Portugal
2
Malaysia
2
Poland
2
Chile
1
Israel
1
Denmark
1
Slovenia
1
Germany
1
Colombia
1
Cyprus
1
Netherlands
1
Ecuador
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic